Factor X inhibitors

Bibliography

• JORDAN RE, OOSTA GM, GARDNER WT, ROSENBERG RD: The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. j. Biol. Chem. (1980) 255:10081–10090.
   PubMed Web of Science ®Google Scholar
• NICHOLSON AC, NACHMAN RL, ALTIERI DC et al.: Effector cell protease receptor-1 is a vascular receptor for coagulation Factor Xa. Biol. Chem. (1996) 271:28407–28413.
   Web of Science ®Google Scholar
• KAISER B, PAINTZ M, SCHOLZ 0 et al.: A synthetic inhibitor of Factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats. Thromb. Res. (2000) 98:175–185.
   Google Scholar
• SCHWARTZ RS, HOLDER DJ, HOLMES DR et al.: Neointimal thickening after severe coronary artery injury is limited by a short-term administration of a Factor Xa inhibitor. Results in a porcine model. Circulation (1996) 93:1542–1548.
   PubMed Web of Science ®Google Scholar
• CIRINO G, CICALA C, BUCCI M et al.: Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of Factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. Clio. Invest. (1997) 99:2446–2451.
   Google Scholar
• SENDEN NH, JEUNHOMME TM, HEEMSKERK JW et al.: Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. Immunol. (1998) 161:4318–4324.
   Web of Science ®Google Scholar
• NIERODZIK ML, PLOTKIN A, KAJUMO F, KARPATKIN S: Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. Clio. Invest. (1991) 87:229–236.
   PubMed Web of Science ®Google Scholar
• BROMBERG ME, KONIGSBERG WH,MADISON JF et al.: Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc. Nati Acad. Sci. USA (1995) 92:8205–8209.
   Google Scholar
• ADIDA C, AMBROSINI G, PLESCIA Jet al.: Protease receptors in Hodgkin's disease: expression of the Factor Xa receptor, effector cell protease receptor-1, in Reed-Sternberg cells. Blood (1996) 88:1457–1464.
   Google Scholar
• NAKATA M, KANEKURA S, MARUYAMA I: DX9065a, an Xa inhibitor, inhibits prothrombin-induced A549 lung adenocarcinoma cell proliferation. Cancer Lett. (1998) 122:127–133.
   PubMed Web of Science ®Google Scholar
• RAUCH BH, BRETSCHNEIDER E, BRAUN M, SCHROR K: Factor Xa releases matrix metalloproteinase-2 (MMP-2) from human vascular smooth muscle cells and stimulates the conversion of pro-MMP-2 to MMP-2: role of MMP-2 in Factor Xa-induced DNA synthesis and matrix invasion. Circ. Res. (2002) 90:1122–1127.
   PubMed Web of Science ®Google Scholar
• OOSTA GM, GARDNER WT, BEELER DL, ROSENBERG RD: Multiple functional domains of the heparin molecule. Proc. Nati Acad. Sci. USA (1981) 78:829–833.
   PubMed Web of Science ®Google Scholar
• BONEU B, NECCIARI J, CARIOU R: Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ Org31540) with high affinity to antithrombin III in man. Thromb. Haemost. (1995) 74:1468–1473.
   PubMed Web of Science ®Google Scholar
• BIJSTERVELD NR, MOONS AH, BOEKHOLDT SM et al.: Ability of recombinant Factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation (2002) 106:2550–2554.
   PubMed Web of Science ®Google Scholar
• •Interesting study which demonstrates the novel use of fVII as a possible antidote to fondaparinux.
   Google Scholar
• ERIKSSON BI, BAUER KA, LASSEN MR et al.: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture Surgery. N Engl. I Med. (2002) 345:1298–1304.
   Web of Science ®Google Scholar
• •Clinical trial of fondaparinux.
   Google Scholar
• BAUER KA, ERIKSSON BI, LASSEN MR et al.: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl. Med. (2002) 345:1305–1310.
   Google Scholar
• •Clinical trial of fondaparinux.
   Google Scholar
• EPHESUS STEERING COMMITTEE: Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet (2002) 359:1715–1720.
   PubMed Web of Science ®Google Scholar
• •Clinical trial of fondaparinux.
   Google Scholar
• TURPIE ACG, BAUER KA, ERIKSSON BI et al.: Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet (2002) 359:1721–1726.
   PubMed Web of Science ®Google Scholar
• •Clinical trial of fondaparinux.
   Google Scholar
• THE REMBRANDT INVESTIGATORS: Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity. Circulation (2000) 102(22):2726–2731.
   PubMed Web of Science ®Google Scholar
• •Clinical trial of fondaparinux.
   Google Scholar
• COUSSEMENT PK, BASSAND JP, CONVENS C et al.: A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur: Heart J. (2001) 22:1716–1724.
   Google Scholar
• •Clinical trial of fondaparinux.
   Google Scholar
• SORELLE R: Cardiovascular news. Circulation (2001) 104(22):E9053–E9055.
   PubMedGoogle Scholar
• •Clinical trial of fondaparinux.
   Google Scholar
• WALENGAJM, JESKE WP, BARA L et Biochemical and pharmacological rationale for the development of a synthetic heparin pentasaccharide. Thromb. Res. (1997) 86:1–36.
   PubMed Web of Science ®Google Scholar
• TURPIE AG, ERIKSSON BI, LASSEN MR, BAUER KA: A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. South Orthop. Assoc. (2002) 11(4):i82–i88.
   Google Scholar
• HARA T, YOKOYAMA A, ISHIHARA H et al.: DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for Factor Xa. Thromb. Haemost. (1994) 71:314–319.
   PubMed Web of Science ®Google Scholar
• DYKE CK, BECKER RC, KLEIMAN NS et al.: First experience with direct factor Xa inhibition in patients with stable coronary disease. Circulation (2002) 105:2385–2391.
   PubMed Web of Science ®Google Scholar
• SATO K, TANIUCHI Y, KAWASAKI T et al.: Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally active Factor Xa inhibitor, and warfarin in mice. fpn..1. Pharmacol. (1998) 78:191–197.
   Google Scholar
• •Good article on the development of an orally active fX inhibitor.
   Google Scholar
• HAN Q, DOMINGUEZ C, STOUTEN PFW et al.: Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors. J. Med. Chem. (2000) 43 (23):4398–4415.
   PubMed Web of Science ®Google Scholar
• BETZ A, WONG PW, SINHA U: Inhibition of factor Xa by a peptidyl--ketothiazole involves two steps. Evidence for a stabilizing conformational change. Biochemistry (1999) 38(44):14582–14591.
   Google Scholar
• SINHA U, KU P, MALINOWSKI J: Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. Eur. Pharmacol (2000) 395(1):51–59.
   PubMed Web of Science ®Google Scholar
• HOLLENBACH S, SINHA U, UN PH et al: A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis. Thromb. Haemost. (1994) 71(3):357–362.
   PubMed Web of Science ®Google Scholar
• WONG PC, CRAIN EJ, KNABB P.M et al: Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis. Pharmacol Exp. Ther: (2000) 295:212–218.
   Google Scholar
• ABENDSCHEIN DR, BAUM PK, MARTIN DJ et al: Effects of ZK-807834, a novel inhibitor of factor Xa on arterial and venous thrombosis in rabbits. Cardiovasc. Pharmacol (2000) 35:796–805.
   PubMed Web of Science ®Google Scholar